Investor Overview

TRACON Pharmaceuticals, Inc. is a fast-growing biotechnology company focused on developing next-generation targeted therapies for the treatment of cancer and related diseases. The company is addressing unmet needs in this arena through product candidates that focus on cellular targets specifically implicated in cancer growth and angiogenesis. TRACON believes that these treatments will offer benefits far exceeding those provided by cytotoxic and first-generation targeted therapies.

TRACON’s experienced management, balanced portfolio, and ability to execute distinguish it from other companies in an increasingly crowded oncology space. For additional information on investing in TRACON, please contact Charles P. Theuer, MD, Ph.D., President and CEO.

Corporate Governance
TRACON’s Board of Directors and management team believe that good corporate governance is critical to our long-term success. Our corporate governance principles, along with the charters and responsibilities of the Board of Directors, provide the framework for the corporate governance of the company.

Corporate Structure
TRACON receives strong financial and infrastructure support from Paramount BioSciences, a leading US drug development and merchant-banking firm. TRACON’s partnership with Paramount addresses operating needs, allowing the company to exclusively devote its resources to candidate selection, product development and front-line business.

Milestones
Since its founding in 2005, TRACON has made strong progress toward its goal of becoming a premier developer of targeted therapeutics. The company has bolstered its management team and research staff through several key hires, and has in-licensed three promising compounds currently in preclinical development. TRACON expects to initiate clinical development of multiple product candidates in 2007, further augment its pipeline and staff, and pursue additional development opportunities as available.

Press Releases

Fact Sheet